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Abstract
Coronary artery calcification (CAC) has been used as a testing modality for coronary atherosclerosis burden. In diabetes, arterial
calcification in the tunica media is common and predicts renal and cardiovascular mortality. It is unknown whether the 2 calcification
processes are related. We identified risk factors associated with lower-extremity arterial calcification (LEAC) and determined its relationship
to the presence of CAC 6 years later and the incidence of complications in type 1 diabetes mellitus. A random sample of 190 participants
from the Pittsburgh Epidemiology of Diabetes Complications Study, a prospective cohort of childhood-onset type 1 diabetes mellitus,
received radiographs of their ankles and feet at the 4-year follow-up examination (1990-1992) and was followed up for approximately 6 years.
At the 10-year examination, 121 of these individuals received an electron beam tomography scan. Male sex (odds ratio [OR] = 12.72,
P b .0001), diabetes duration (OR = 4.53, P b .0001), and autonomic neuropathy (AN; OR = 5.92, P = .007) independently increased the
odds of LEAC. Controlling for other known risk factors (duration and high-density lipoprotein cholesterol), we found that LEAC correlated
with the presence of CAC 6 years later (OR = 1.12, P = .03), although adjusting for neuropathy attenuated this relationship (P = .08). LEAC
also independently predicted AN but not the onset of other diabetes complications. Although arterial calcification in the lower extremities and
the heart share many of the same risk factors, LEAC is an independent correlate of the later presence of CAC and AN. Thus, factors related to
the calcification process in addition to vascular risk factors may play a role in determining the extent of CAC.
D 2006 Elsevier Inc. All rights reserved.1. Introduction
Individuals with type 1 diabetes mellitus have been shown
to have up to a 10-fold increased risk for coronary artery
disease (CAD) and mortality [1,2]. Lower-extremity arterial
calcification (LEAC) is also common and has been shown to
be associated with many traditional CAD risk factors and to
CAD itself [3-6]. In diabetes, LEAC has also been related
to renal failure and early mortality [7,8]. Coronary artery
calcification (CAC) has previously been cross-sectionally
correlated with CAD events in individuals with type 1
diabetes mellitus [9], and as such could potentially serve as an
early marker of CAD. However, little is known concerning
the association of LEAC with CAC and to what extent this
may reflect shared risk factors. Moreover, as LEAC occurs
mainly in the medial wall (Mfnckeberg sclerosis) and CAC is0026-0495/$ – see front matter D 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.metabol.2006.08.012
4 Corresponding author. Tel.: +1 412 383 1032; fax: +1 412 383 1020.
E-mail address: tjo@pitt.edu (T.J. Orchard).thought to reflect plaque calcification, any association may
also reflect the calcification process in general. Few, if any,
studies to date have examined the relationship of LEAC with
CAC in type 1 diabetes mellitus and compared their
respective risk factors.
This analysis sought to identify risk factors associated
with LEAC and to determine its relationship to the later
presence of CAC in a cohort of individuals with type 1
diabetes mellitus in the setting of traditional risk factors. We
also examined the relationship of LEAC to the development
of other diabetes complications.2. Research design and methods
Subjects for the analysis were participants of the
Pittsburgh Epidemiology of Diabetes Complications
(EDC) study. The EDC study, a 10-year prospective
follow-up study of childhood-onset type 1 diabetes mellitus,
has been previously described in detail [10]. Briefly,perimental 55 (2006) 1689–1696
T. Costacou et al. / Metabolism Clinical and Experimental 55 (2006) 1689–16961690participants were diagnosed (or seen within 1 year of
diagnosis) between 1950 and 1980, before their 17th
birthday, at the Children’s Hospital of Pittsburgh. This
population has been shown to be representative of the type 1
diabetes mellitus population in Allegheny County, Pennsyl-
vania [11]. Six hundred fifty-eight subjects met eligibility
criteria and were first examined for the EDC study between
1986 and 1988. During the third biennial examination
(1990-1992), a random subgroup of 190 participants had
radiographs taken of their ankles and feet. During the
10-year follow-up examination (1996-1998), electron beam
tomography (EBT) screening was initially (June 11, 1997)
made available to all attending participants aged 30 years or
older, and subsequently (October 15, 1997) to all partic-
ipants aged 18 years or older. A total of 304 participants
underwent EBT screening [9], including 121 who had
previously undergone radiographs to look for LEAC. The
third biennial examination (1990-1992) was considered as
baseline for the present analysis.
2.1. Definition of risk factors and outcome measures
LEAC was graded as 0, absent; 1, barely visible; 2,
specific outline; or 3, very dense (N2 cm) at 6 locations,
namely, in the tibialis anterior, dorsalis pedis, and tibialis
posterior arteries at the ankle level, and the plantaris,
metatarsal, and digital arteries in the foot. LEAC was
independently assessed by 2 observers (TJO, SJW). In case
of disagreements, the observers discussed the x-rays
together and agreed on a score. These x-rays were also
independently reviewed by investigators in the Netherlands
(Dr Ronald Stolk and Dr Willemijn Klein). A composite
LEAC score was calculated using a cumulative index
(summation) of the scores from all of the 12 scoring
locations on both of the lower limbs. Only linear calcifica-
tion in the ankle x-rays, the characteristic of medial wall
arterial sclerosis, was included in the LEAC score [12-15].
Scorer agreement (Netherlands vs Pittsburgh) for the cu-
mulative index score was moderate (Spearman q = 0.66,
P b .0001). LEAC was further quantified by dichotomizing
the scores as bany LEACQ or bno LEACQ (j statistic for the
Netherlands vs Pittsburgh interobserver agreement = 0.89,
P b .0001). To maximize accuracy, sample size, and
information provided by the LEAC score, an ordinal
variable was created by categorizing the distribution of the
composite LEAC score into 3 groups. Those with no LEAC
(n = 56) composed the lowest group. A median split was
then used to divide the remaining individuals into 2 groups,
one with a composite LEAC score of 1 to 6 (n = 29) and a
third group with LEAC values of 7 to 24 (n = 35). All
analyses were based on the radiograph scoring done in
Pittsburgh.
CAC was assessed via EBT using a GE-Imatron ultrafast
computed tomography scanner (GE-Imatron, San Francisco,
CA). Scans were triggered by electrocardiogram (ECG)
signals at 80% of the R-R interval and obtained in 3-mm
contiguous sections of the heart. CAC was calculated by theAgatston method of scoring, using the number, area, and
peak Hounsfield units of calcified lesions [16]. A lesion
score was calculated by multiplying the density score and
the area, and a total calcium score was determined by adding
up each of these scores for all slices.
All other complications and risk factors were assessed at
the same time as the LEAC (ie, 1990-1992) and were
assessed as correlates of CAC (1996-1998). CAD was
defined as EDC physician-diagnosed angina, myocardial
infarction confirmed by Q waves on an ECG (Minnesota
codes 1.1 or 1.2) or through hospital records, angiographic
stenosis of 50% or higher, coronary artery bypass surgery,
angioplasty, or ischemic ECG changes (Minnesota codes
1.3, 4.1-4.3, 5.1-5.3, and 7.1). Hypertension was character-
ized as a blood pressure of 140/90 mm Hg or higher or
current treatment with antihypertensive medications. Gly-
cosylated hemoglobin (HbA1) level was measured by auto-
mated high-performance liquid chromatography (Diamat,
BioRad, Hercules, CA). Cholesterol and triglycerides were
measured enzymatically [17,18]. High-density lipoprotein
(HDL) cholesterol was determined by using a modified [19]
heparin and manganese chloride precipitation technique of
the Lipid Research Clinics method [20]. Low-density
lipoprotein (LDL) cholesterol was calculated by using the
Friedewald equation [21]. Non-HDL cholesterol was
calculated as total minus HDL cholesterol. Plasminogen
activator inhibitor 1 (PAI-1) concentrations were determined
as previously described [22] by an enzyme-linked immu-
nosorbent assay procedure (American Bioproducts, Parsip-
pany, NJ) [23]. Fibrinogen levels were measured by using a
biuret colorimetric procedure and a clotting method.
Serum and urinary albumin were measured by immu-
nonephelometry [24,25], and creatinine level was assayed
by an Ectachem 400 Analyzer (Eastman Kodak, Rochester,
NY). Overt nephropathy (ON) was defined as albumin
excretion rate (AER) greater than 200 lg/min in 2 of
3 timed urine collections or, in the absence of urine, a
serum creatinine level greater than 153 lmol/L (N2 mg/dL),
or renal failure or renal transplantation. Distal symmetric
polyneuropathy was assessed according to the signs and
symptoms identified in the Diabetes Control and Compli-
cations Trial protocol [26] and was confirmed by using a
Vibraton II (Physitemp Instruments, Clifton, NJ) at or after
the 4-year follow-up examination (confirmed distal sym-
metric polyneuropathy [CDSP]) by the presence of an age-
specific vibratory threshold above the reference range.
Autonomic neuropathy (AN) was assessed by measuring
heart rate response to deep breathing (expiration-inspiration
ratio). A ratio of less than 1.1 was considered abnormal
[27]. Proliferative retinopathy (PR) was assessed by stereo
fundus photography using the Arlie House System of
classification [28] or a history of laser treatment for
proliferative disease. Lower-extremity arterial disease
(LEAD) was defined as an ankle-brachial index less than
0.9 [29], or claudication, or by a history of amputation for a
vascular cause.
Table 1
Univariate risk factors associated with any lower-extremity ankle calcification (the Pittsburgh EDC study 1990-1992)
Characteristics LEAC No LEAC OR (95% CI) Spearman q
n 64 57 – –
Age (y) 36.6 F 6.0 28.7 F 6.3 4.12 (2.43-6.98)4444 0.494444
Diabetes duration (y) 27.9 F 6.6 19.6 F 6.7 3.80 (2.31-6.27)4444 0.484444
% Male 57.8 (37) 28.1 (16) 3.51 (1.64-7.52)44 –
% Hypertension 31.3 (20) 10.5 (6) 3.86 (1.43-10.48)44 –
% Ever smoked (n = 63, 56) 36.5 (23) 32.1 (18) 1.21 (0.57-2.60) –
Smoking now (%, n) (among ever smokers) 26.1 (6) 55.6 (10) 0.28 (0.08-1.05) –
% CAD 26.6 (17) 10.5 (6) 3.07 (1.12-8.45)4 –
% ON 32.8 (21) 12.3 (7) 3.49 (1.35-9.00)44 –
% CDSP (n = 63, 56) 33.3 (21) 7.1 (4) 6.50 (2.07-20.40)44 –
% PR 56.3 (36) 28.6 (16) 3.21 (1.50-6.88)44 –
% AN (n = 61, 54) 41.0 (25) 20.4 (11) 2.71 (1.18-6.26)4 –
% LEAD 12.5 (8) 10.5 (6) 1.21 (0.39-3.74) –
BMI (kg/m2) 25.1 F 3.2 23.9 F 3.5 1.47 (0.999-2.16) 0.204
SBP (mm Hg) 119.8 F 18.6 109.8 F 14.7 1.94 (1.25-3.01)44 0.2844
DBP (mm Hg) 73.2 F 9.5 68.9 F 7.7 1.69 (1.14-2.51)44 0.2544
HbA1 (%, n = 62, 56) 10.7 F 1.7 10.5 F 1.4 1.14 (0.79-1.64) 0.06
Total cholesterol (mg/dL, n = 63, 57) 192.4 F 38.2 179.6 F 37.6 1.42 (0.97-2.07) 0.18
HDL-C (mg/dL, n = 63, 57) 51.5 F 9.5 55.3 F 12.1 0.69 (0.47-1.02) 0.17
LDL-C (mg/dL, n = 55, 51) 118.3 F 31.0 107.1 F 28.8 1.47 (0.98-2.19) 0.15
Non–HDL-C (mg/dL, n = 63, 57) 140.9 F 38.1 124.3 F 36.3 1.60 (1.08-2.37)4 0.2644
Triglycerides (mg/dL, n = 55, 51)a 93.1 F 64.5 74.4 F 35.8 1.51 (0.94-2.42) 0.15
BDI (n = 61, 53)b 7.9 F 7.1 5.5 F 6.9 1.44 (0.96-2.15) 0.214
Fibrinogen (mg/dL, n = 62, 57)a 315.2 F 105.3 286.6 F 87.5 1.37 (0.93-2.02) 0.14
WBC count ( 103, n = 63, 56)a 7.4 F 2.7 7.2 F 2.2 1.11 (0.76-1.60) 0.01
Serum creatinine (mg/dL, n = 63, 57)b 1.2 F 0.94 0.90 F 0.37 3.19 (1.19-8.57)4 0.354444
PAI-1 (mg/dL, n = 62, 55)a 23.5 F 14.9 24.7 F 15.7 0.92 (0.64-1.33) 0.05
AER (lg/min)b 267.7 F 600.1 150.8 F 422.9 1.28 (0.85-1.93) 0.2544
Data are means F SD or % (n). ORs (95% confidence intervals [CIs]) are per 1 SD increase in continuous variables. SBP indicates systolic blood pressure;
DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; WBC, white blood cell.
a Natural log-transformed.
b Wilcoxon rank sum test.
4 P V .05.
44 P V .01.
444 P V .001.
4444 P V .0001.
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questionnaires concerning demographic information, health
care, medical history, and physical activity. Smoking status
(ever/never or current) and Beck Depression Inventory
(BDI) [30] were self-reported.3. Statistical analysis
Univariate associations of risk factors to LEAC or CAC
score were evaluated by using the v2 test or the Student t
test. Continuous variables were normalized by using
logarithmic transformation where appropriate (ie, triglycer-
ide level, fibrinogen concentration, white blood cell count,
PAI-1, and BDI score), or, if this was not possible (ie, serum
creatinine level and AER), the Wilcoxon rank sum test was
used. Results were considered significant at P less than .05.
The Cochran-Armitage test for trend was used to examine
the possibility of a dose-response effect in the relationship
of LEAC to CAC.
Because of the high number of subjects with no
calcification (n = 66), a two-stage regression approachwas used to examine multivariate correlates of CAC. In the
first stage, multiple logistic regression was used to assess
the development of CAC (any vs none). All univariate
significant correlates of the presence of any CAC were
allowed to enter the stepwise selection process and
variables were required to have a P value of .10 or less
to remain in model 1. Model 2 further allowed for LEAC
status, whereas subsequent models also allowed for the
presence of diabetes complications one at a time. In the
second stage, multiple linear regression was used to
identify the factors associated with higher amounts of
CAC, conditional upon having a CAC score greater than
zero. LEAC was modeled as a categorical variable with 3
levels. The relationship of LEAC to the development of
several diabetes complications (including AN, CAD, CDSP,
PR, ON/renal failure, and mortality) was modeled by using
Cox proportional hazard models with entry and exit criteria
of P of .05 or less and P of .10 or less, respectively.
Duration of diabetes was forced into all statistical models.
The Akaike information criterion (AIC) was used to select
the best model. Statistical analyses were performed with
Table 2
Independent risk factors (1990-1992) that are associated with the presence
of LEAC: multiple logistic regression analysis (n = 105, 55 cases) (the
Pittsburgh EDC study)
Variable OR (95% CI) P
Duration of diabetes (y) 4.53 (2.32-8.85) b .0001
Sex (male) 12.72 (3.66-44.27) b .0001
AN status 5.92 (1.62-21.60) .007
AIC 99.379
Risk factors made available for the stepwise modeling process included those
significant in a univariate fashion (diabetes duration, sex, BMI, hypertension,
HDL, non-HDL, CAD, ON, CDSP, PR, AN, serum creatinine level). Risk
factors were required to be significant in the model at the P b .10 level. The
OR for diabetes duration is presented per 1 SD increase (SD = 7.84 years).
T. Costacou et al. / Metabolism Clinical and Experimental 55 (2006) 1689–16961692SAS statistical software version 9.1 for windows (SAS
Institute, Cary, NC).
4. Results
CAC scans were introduced during the 10-year examina-
tion cycle (June 11, 1997) because of a sudden availability ofTable 3
Baseline risk factors (1990-1992) by the subsequent presence of CAC (the Pittsb
Characteristics CAC No CAC
n 55 66
Age (y) 37.2 F 6.2 29.2 F
Duration of diabetes (y) 28.4 F 6.8 20.3 F
% Male 47.3 (26) 40.9 (27
% LEAC 74.6 (41) 34.9 (23
Composite LEAC scorea 6.6 F 6.2 2.3 F
% Hypertension 34.6 (19) 10.6 (7)
% Ever smoked 39.6 (21) 30.8 (20
Smoking now (%, n)
(among ever smokers)
42.9 (9) 35.0 (7)
% CAD 25.5 (14) 13.6 (9)
% ON 34.6 (19) 13.6 (9)
% CDSP 40.0 (22) 4.7 (3)
% PR 63.6 (35) 26.2 (17
% AN 49.1 (26) 16.1 (10
% LEAD 16.4 (9) 7.6 (5)
BMI (kg/m2) 25.4 F 3.7 23.9 F
SBP (mm Hg) 121.3 F 20.0 109.9 F
DBP (mm Hg) 73.1 F 9.5 69.5 F
HbA1 (%) 10.6 F 1.5 10.6 F
Total cholesterol (mg/dL) 193.9 F 37.6 180.1 F
HDL-C (mg/dL) 51.1 F 8.8 55.0 F
LDL-C (mg/dL) 119.5 F 27.9 108.2 F
Non–HDL-C (mg/dL) 142.7 F 39.6 125.1 F
Triglycerides (mg/dL)b 96.3 F 68.7 75.5 F
BDIa 8.1 F 7.4 5.7 F
Fibrinogen (mg/dL)b 325.1 F 104.8 281.9 F
WBC count (103)b 7.8 F 3.0 6.9 F
Serum creatinine (mg/dL)a 1.3 F 1.0 0.91 F
PAI-1 (mg/dL)b 24.6 F 14.9 23.6 F
AER (lg/min)a 281.4 F 596.4 155.3 F
Data are means F SD or % (n). ORs (95% CIs) are per 1 SD increase in contin
a Wilcoxon rank sum test.
b Natural log-transformed.
4 P V .05.
44 P V .01.
444 P V .001.
4444 P V .0001.funding, initially to all those aged 30 years or older and
subsequently (October 15, 1997) to all younger individuals
(all aged 18 years or older). Thus, at the time of the original
LEAC determination, persons with a subsequent EBT were
older than those without a scan. They were also more likely
to be women, less likely to smoke, and had a better lipid
profile and HbA1 levels. They were also more likely to have
AN (not shown). However, there was little self-selection,
scanning being determined primarily by funding and age.
Approximately 79% of persons older than 30 years attending
the exam had an EBT when it was available. At follow-up
(when EBT was made available), those with and without an
EBT did not differ except for an older age, a lower
prevalence of smoking, a higher prevalence of AN, and
lower systolic blood pressure in those with an EBT.
4.1. LEAC risk factor profile
Table 1 shows the cross-sectional correlates of LEAC at
baseline (1990-1992). Subjects with LEAC were signifi-
cantly older, had a longer duration of diabetes, and wereurgh EDC study 1996-1998)
OR (95% CI) Spearman q
– –
6.0 4.25 (2.50-7.24)4444 0.564444
6.6 3.44 (2.15-5.51)4444 0.524444
) 1.30 (0.63-2.67) –
) 7.01 (3.01-10.33)4444 –
4.3 1.19 (1.09-1.30)4444 0.444444
4.45 (1.70-11.63)44 –





) 4.94 (2.27-10.78)4444 –
) 5.01 (2.11-11.89)444 –
2.39 (0.75-7.60) –
3.0 1.56 (1.06-2.29)4 0.194
13.1 2.00 (1.33-3.00)444 0.31444
8.1 1.57 (1.04-2.38)4 0.16
1.5 1.03 (0.69-1.56) 0.03
38.2 1.46 (0.99-2.14) 0.184
12.2 0.67 (0.44-1.01) 0.13
31.3 1.51 (0.98-2.32) 0.214
35.1 1.65 (1.11-2.45)4 0.2344
37.1 1.78 (0.97-3.25) 0.13
6.7 1.42 (0.97-2.08) 0.214
87.7 1.61 (1.07-2.41)4 0.224
1.8 1.44 (0.96-2.17) 0.12
0.26 2.84 (1.22-6.64)4 0.224
15.6 1.08 (0.70-1.68) 0.06
454.6 1.41 (0.83-2.38) 0.2844
uous variables.
Fig. 1. Prevalence of CAC by composite LEAC score (n = 121). The
Pittsburgh EDC study. Cochran-Armitage test for trend, P b .0001.
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all of the major complications except for LEAD prevalence.
Individuals with LEAC also displayed a poorer lipid profile,
had higher blood pressures, and were more likely to be
hypertensive. Inflammatory markers were not increased in
those with LEAC although BDI scores were. There was no
difference in HbA1 or smoking status.
One hundred five individuals had complete information
for all covariates considered in multivariable analyses. In a
stepwise multiple logistic regression process that controlled
for duration of diabetes, male sex (OR = 12.72, P b .0001),
and AN (OR = 5.92, P = .007) were found to independently
increase the odds of a subject having LEAC (Table 2).
4.2. CAC correlates
The comparisons between the risk factors (measured in
1990-1992) of subjects who 6 years later (1996-1998) were
found to have CAC and those who did not (mean follow-up
time = 6.2 F 0.70 years) are presented in Table 3. Subjects
who had CAC later were significantly older and had a
longer duration of diabetes; however, there were no differ-
ences in sex, smoking status, and HbA1. They had higher
blood pressures and were more likely to be hypertensive and
have major microvascular complications, although no
significant differences were seen for either CAD or LEAD,Table 4
Independent baseline risk factors (1990-1992) that are associated with the subse
(n = 105; 48 with CAC) (the Pittsburgh EDC Study)
Variable Model 1 M
Diabetes duration (y) 4.44 (2.31-8.52), P b .0001 4.
BMI (kg/m2) Not selected 1.
HDL-C 0.52 (0.29-0.93), P = .03 0.
LEAC category 1.12 (1.01-1.24), P = .03 1.
CDSP Not available 20
AN Not available N
AIC 102.379 90
Values are presented as OR (95% CI), P. Model 1 allowed for diabetes duration, s
ON, and LEAC category. Model 2 allowed for variables in Model 1, in addition t
AN. ORs are presented per 1 SD increase for continuous variables.which had a lower prevalence. The presence of CAC was
further distinguished by a somewhat more adverse lipid
profile 6 years earlier. Of particular note was the strong
association between LEAC and CAC 6 years later (Spear-
man q = 0.44, P b .001). This is shown graphically in Fig. 1.
4.3. Multivariable correlates of CAC using LEAC
In stepwise multiple logistic regression (n = 105), LEAC
was significantly associated with the later presence of CAC
(Table 4, model 1). Other factors considered were diabetes
duration, sex, body mass index (BMI), HDL and non-HDL
cholesterol levels, hypertension, fibrinogen concentration,
serum creatinine level, and ON status. When additional
models were constructed further adjusting for the presence
of diabetes complications (one at a time), the effect of
LEAC was not altered with the exception of models
including the 2 neuropathy measures, namely, CDSP and
AN, where the effect of LEAC was attenuated (P = .08).
When compared with subjects with no LEAC, the group
with the most LEAC (composite LEAC score z7) had a
6-fold increased risk for the later presence of CAC (OR =
6.31, P = .003). In the subgroup of subjects with later CAC
(n = 55), stepwise multiple linear regression revealed that
LEAC was not a significant independent correlate of the
extent of CAC (not shown). However, in this subgroup, the
nature of the relationship between LEAC and CAC score
remained of a positive nature (Spearman q = 0.21, P = .12).
Cox proportional hazard modeling was also used to look
at the 6-year incidence of diabetes complications between
the 4-year and the 10-year biennial examination. Controlling
for duration of diabetes and other risk factors, LEAC
showed no independent effect on the incidence of CAD
(n = 32) or PR (n = 27). However, LEAC was independently
related to the incidence of AN (n = 29, p = .03). To further
explore the link with AN, further assessments of AN
(expiration-inspiration ratio b1.1, difference of supine to
standing systolic blood pressure N10 mm Hg, ratio of
maximal R-R interval at the 30th beat to the shortest R-R
interval at the 15th beat after standing V1.04) available at
follow-up were treated as outcomes, and LEAC from the
biennial examination during 1990-1992 was found to bequent presence of CAC (1996-1998): multiple logistic regression analysis
odel 2 Model 3
06 (2.08-7.93) P b .0001 4.75 (2.21-10.22), P b .0001
94 (0.96-3.94), P = .06 2.18 (1.08-4.43), P = .03
56 (0.28-1.10), P = 0.09 0.46 (0.23-0.95), P = .04
10 (0.99-1.22), P = 0.08 1.10 (0.99-1.22), P = 0.08
.55 (3.00-140.67), P = .002 Not available
ot available 10.79 (2.64-44.07), P = .0009
.764 91.441
ex, BMI, hypertension, HDL, non-HDL, fibrinogen, serum creatinine level,
o CDSP. Model 3 allowed for variables included in Model 1, in addition to
T. Costacou et al. / Metabolism Clinical and Experimental 55 (2006) 1689–16961694univariately related to the expiration-inspiration ratio (P =
.0003) and to the difference of supine to standing systolic
blood pressure (P = .08) but not to the 30:15 ratio (P = .50).5. Discussion
This article examined the risk factor profile of LEAC and
its relationship with the later presence of CAC by taking
known CAD risk factors into account in a cohort of
participants with type 1 diabetes mellitus. The results
demonstrated an increasing prevalence of CAC 6 years
later based on the amount of LEAC they had at baseline.
This relationship was independent of all other known
correlates of CAC in this cohort, although it was attenuated
when controlling for neuropathy status.
Interestingly, the risk factors that were cross-sectionally
associated with the presence of LEAC also, for the most
part, correlated with the later presence of CAC, at least in a
univariate fashion. Thus, subjects with high LEAC who
later show CAC had several common traits: they were more
likely to be older, hypertensive, have neuropathy, and have a
poorer lipid profile. These similarities between the risk
factor profiles of subjects with LEAC and subjects with
CAC might suggest a common pathogenesis for arterial
calcification in both locales. Conversely, although a much
higher proportion of participants with LEAC was male, this
male preponderance was not observed in CAC. This
leveling of sex differences in the presence of calcium in
the coronary arteries in type 1 diabetes mellitus compared to
nondiabetic populations has been shown previously
[9,31,32]. However, it is difficult to draw conclusions from
these data on whether the excess male presence in the LEAC
group denotes an early sex difference in calcification
overall that later disappears or whether sex differences exist
in the calcification of the lower extremities but not the
coronary arteries.
LEAC remained a correlate of the later presence of CAC
independent of most risk factors, indicating that LEAC may
explain CAC variation beyond standard CAD risk factors.
Its effect, however, was attenuated after adjustment for
neuropathy status. Previous studies have suggested that AN
is a key determinant of medial calcification in patients with
diabetes [33,34] and that it is associated with cardiovascular
risk factors [35]. Thus, it could be argued that LEAC is
merely a marker of neuropathy, and not itself an indepen-
dent risk factor. Our data would suggest otherwise, as LEAC
did improve the model fit. Furthermore, this issue was also
assessed by Mayfield et al [34] who showed that AN could
not entirely explain the excess mortality, amputation, and
ulceration in persons with medial arterial calcinosis. This
important observation, in addition to our results, may
suggest that there might be more to the LEAC-CAC
association beyond a shared link with neuropathy. Curious-
ly, LEAC was not associated with the extent of CAC among
individuals with at least some CAC, although the small
sample size may limit power in these analyses.Little research is available that examines the relationship
between different locales of arterial calcification. However,
some data are available that look at the relationship of
peripheral vascular disease and CAD. In an earlier EDC
analysis by Olson et al [9], peripheral vascular disease
(defined as ABI b0.8, history of claudication, amputa-
tion from vascular cause, or ankle-brachial difference of
z75 mm Hg) was found to be cross-sectionally related to
CAC in both men and women. In this analysis, a high ABI
was used as a surrogate marker of LEAC and was found to
be significantly related to CAC. These previous results are
strengthened by our analysis, which used a stronger marker
of actual LEAC instead of surrogate markers. The study by
Iribarren et al [36] showed an increasing rate of peripheral
vascular disease in both men and women who also had
aortic arch calcification, although the difference did not
reach statistical significance.
Despite the modest sample size used in this analysis
(n = 121), the extended follow-up period (6.2 F 0.70 years)
lends strength to the results. The scoring methodology used
for the quantification of LEAC was more quantitative than
the scoring system used in most of the current literature that
classifies calcification as either bpatchyQ/intimal or linear in
nature [13]. Conversely, the presence of calcium in the
coronary arteries is an indication of intimal atherosclerosis
[37]. The scarcity of reports demonstrating CAC being
present in the absence of atherosclerotic plaque, in addition
to the strong pathophysiologic data demonstrating that EBT
represents intimal calcification [38-40], further shows that
EBT scans do indeed measure atherosclerotic plaque.
The lack of any strong associations between LEAC and
the incidence of diabetes complications is in contrast to
some findings that have suggested that LEAC is prospec-
tively associated with increased mortality [4], amputations
[4,15,41], nephropathy [4,5], retinopathy [4,5], and CAD
[4,15]. However, the modest size of this study population
may limit our power in these analyses. Other limitations
include the determination of LEAC and CAC status at
different time points, allowing only for inferences regarding
correlation but not prediction. Different methodologies were
used for detecting calcium in the lower extremities and the
coronary arteries. As EBT is more sensitive compared to
plain films, it is possible that the calcification detected in the
lower extremities represents more severe disease compared
with the calcification detected in the coronary arteries.
Furthermore, although we tried to standardize the ankle
x-ray data and plain film acquisition by having the same
technician, whenever possible, obtain x-rays (and by
seeking consensus of the 2 observers for all x-rays), in the
cases where different technicians were involved it is
possible that different tissue depths and findings could have
occurred. It is likely, however, that such variation would
only introduce noise and not systematic bias. Finally, when
compared with participants without an EBT, those with a
scan showed some baseline differences, notably age, as
initially, scans were offered to those aged 30 years or older.
T. Costacou et al. / Metabolism Clinical and Experimental 55 (2006) 1689–1696 1695However, the differences, with the exception of older age,
were less marked comparing those with and without an EBT
at the examination cycle when scans were offered. Thus, our
results may not be fully generalizable to the total type 1
diabetes mellitus population and may have, to a small
extent, underestimated true coronary calcification. Nonethe-
less, it is unlikely that these differences may have led to
spurious associations between LEAC and CAC within the
group studied.
There are a number of interpretations of the results of this
study, beyond the observation that the risk factors for LEAC
and CAC are similar and that LEAC may be a useful
correlate of CAC. The nature of this association may simply
reflect the fact that atherosclerotic risk factors predict both
peripheral and coronary calcification despite the former
(LEAC) reflecting medial wall calcification of the
Mfnckeberg type and the latter reflecting atherosclerotic
plaque. The second interpretation is that the association of
LEAC and CAC reflects an increased susceptibility to
calcification per se. This would seem a possibility worthy of
future research and may help to refine the role of CAC in
CAD prediction. A number of studies have reported on the
association between specific gene variants and CAC
[42-47]. Although results are not always consistent, certain
of these genes may also predict cardiovascular disease
[48-50]. If a subgroup of individuals have CAC largely on
the basis of a tendency to calcify, as can generally be sug-
gested by these results, rather than be a reflection of athe-
rosclerosis per se, the identification of this subgroup would
help refine the value of CAC as a predictor of CAD events
because it could identify some potential false positives.
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